• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr Richard Willke Previews ISPOR 2017 in Boston

Video

Richard J. Willke, PhD, chief science officer of ISPOR, previews the discussions at the ISPOR 22nd Annual International Meeting, which will be held May 20-24 in Boston, Massachusetts, including topics on the future of health policy in the United States and social networking interventions.

Richard J. Willke, PhD, chief science officer of ISPOR, previews the discussions at the ISPOR 22nd Annual International Meeting, which will be held May 20-24 in Boston, Massachusetts, including topics on the future of health policy in the United States and social networking interventions.

Transcript

As ISPOR prepares for the annual meeting in Boston in May, how is it handling the uncertainty of an Affordable Care Act repeal? What other topics will the meeting focus on?

Our first plenary in Boston is going to feature a panel of 4 leading health economists. Two that have worked with the Democrats—Jonathan Gruber and David Cutler—and 2 that have tended to work with Republicans—Joe Antos and Gail Wilensky. Given what just happened [with the American Health Care Act] we expect it to be a very lively discussion.

Our second plenary is on the leading edge of how we look at healthcare behaviors. It's called "Social Networking Interventions and Population Health." And it's being given by Nicholas Christakis of Yale. I'm really anxious to hear that one. And our third one will be very aligned with what we talked about [at AMCP 2017]. The title is "When Do You Really Need Randomized Clinical Trials?" And we'll have Sebastian Schneeweiss and Rob Califf, who was just FDA commissioner, and Steven Goodman to talk about those topics.

Plus, about another 100 sessions on a variety of current scientific and policy topics. So we're really excited about it.

Related Videos
Debra Boyer, MD, MHPE, ATSF.
Video 2 - "Payer Needs and Strategies for Evaluating and Covering PDTs"
Video 1 - "Differentiating PDTs from Wellness Apps and Evaluating Efficacy"
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
ISPOR 2024 Recap
Chris Pagnani, MD, PC
Video 4 - "Oral SERDs in Development for ER+/HER2- Metastatic Breast Cancer"
Video 3 - "The Role of Oral SERDs in ER+/HER2- Metastatic Breast Cancer"
Screenshot of Stephen Freedland, MD, during a video interview
Phaedra Corso, PhD, associate vice president for research at Indiana University
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.